CACNA1G and insomnia: In this study, the biological studies revealed that compound 2 can strongly and dose-dependently inhibited the peak currents of Cav3.1 low voltage-gated Ca2+ channel (LVGCC), an important therapeutic target for absence epilepsy, neuropathic pain, Parkinson’s disease, and insomnia [20–22], with an IC50 value of 3.5 μM. Meanwhile, 1, 3, and 4 were inactive at the concentration of 30 μM. In this note, the isolation and structural elucidation of these compounds were described, as well as their inhibitions on Cav3.1 LVGCC.